Vasculitis and Giant Cell Arteritis

Top Story

Half of GCA patients receiving tocilizumab remained in remission 2 years after withdrawal

Half of GCA patients receiving tocilizumab remained in remission 2 years after withdrawal
November 14, 2019
Meeting NewsPerspective

Vasculitis guidelines support first-line biologic therapies in certain patients

November 14, 2019
ATLANTA — Increased use of glucocorticoid-sparing agents is one of the key recommendations in a guideline document that covers seven vasculitis diseases, according…
Meeting News

Gadolinium-enhanced MRI improves diagnostic accuracy in polymyalgia rheumatica

November 14, 2019
ATLANTA — Gadolinium-enhanced MRI improved diagnostic accuracy in patients with polymyalgia rheumatica and helped predict disease recurrence, according to a…
Meeting News

GCA, Takayasu’s and polyarteritis nodosa: Implementing ACR guidelines

November 12, 2019
ATLANTA — A panel at ACR/ARP 2019 offered an overview of the new guidelines for giant cell arteritis, Takayasu’s syndrome, and polyarteritis nodosa. …
More Headlines »
CME ABIM MOC

Ace the Case: A 73-Year-Old Woman With Abrupt Onset of Transient Left-Sided Diplopia

There is no commercial support for this activity.

This educational activity will utilize a case study to assess the diagnosis and management of a 73-year-old woman with…
More »
Video
Meeting News

VIDEO: "Modest associations" found between baseline factors, steroid use

December 22, 2016
More »
CME ABIM MOC

3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp - Best Of!

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Immune-mediated inflammatory diseases (IMIDs) are a group of clinically heterogeneous disorders, including rheumatoid…
More »